The Money of Sequencing | GenomeWeb

There has been an increasing number of cases in which people have been helped medically by knowing their genome, and Forbes' Matthew Herper adds that "these pioneers have followed a path we're all likely to trod down — and one that the business world has not even begun to figure out how to monetize." Herper goes on to say that while the price of DNA sequencing is falling quickly — he mentions the price war between Illumina and Life Tech as well as the in

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

And, Poof, It's Gone

Changes Ahead

To Spot it Early

Cancer Trial Halted

Promising Trial

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.